Will NVIDIA Return to Its 52-Week High?
NVIDIA (NASDAQ:NVDA) has been among the best-performing investments of the…
Sell
43
QGEN Quote, Financials, Valuation and Earnings
Last price:
$41.97
Seasonality move
:
3.23%
Day range:
$40.77 - $42.40
52-week range:
$37.63 - $49.30
Dividend yield:
0%
P/E ratio:
112.24x
P/S ratio:
4.66x
P/B ratio:
2.54x
Volume:
1.7M
Avg. volume:
1.3M
1-year change:
-0.87%
Market cap:
$9.1B
Revenue:
$2B
EPS (TTM):
$0.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QGEN
Qiagen NV
|
$507.1M | $0.56 | 2.17% | 31.38% | $49.48 |
|
CDT
Conduit Pharmaceuticals
|
-- | -- | -- | -- | -- |
|
IFRX
InflaRx NV
|
$25.4K | -$0.15 | -5.26% | -0.05% | $9.24 |
|
LENZ
LENZ Therapeutics
|
-- | -$0.40 | -- | -82.44% | $42.63 |
|
MAZE
Maze Therapeutics
|
$4.2M | -$0.64 | -- | -- | $25.67 |
|
ORKA
Oruka Therapeutics
|
-- | -$0.52 | -- | -35.68% | $39.86 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QGEN
Qiagen NV
|
$41.98 | $49.48 | $9.1B | 112.24x | $1.30 | 0% | 4.66x |
|
CDT
Conduit Pharmaceuticals
|
$0.91 | -- | $8.7M | -- | $0.00 | 0% | -- |
|
IFRX
InflaRx NV
|
$0.92 | $9.24 | $62M | -- | $0.00 | 0% | 299.60x |
|
LENZ
LENZ Therapeutics
|
$20.26 | $42.63 | $558M | -- | $1.03 | 0% | -- |
|
MAZE
Maze Therapeutics
|
$7.83 | $25.67 | $335.3M | -- | $0.00 | 0% | -- |
|
ORKA
Oruka Therapeutics
|
$7.68 | $39.86 | $287.5M | -- | $19.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QGEN
Qiagen NV
|
28.06% | 0.222 | 14.06% | 2.76x |
|
CDT
Conduit Pharmaceuticals
|
-- | 1.498 | -- | -- |
|
IFRX
InflaRx NV
|
-- | 4.794 | -- | 3.85x |
|
LENZ
LENZ Therapeutics
|
-- | 1.895 | -- | -- |
|
MAZE
Maze Therapeutics
|
-- | 0.000 | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -3.805 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QGEN
Qiagen NV
|
$333.3M | $141.2M | 1.63% | 2.33% | 26.28% | $141.9M |
|
CDT
Conduit Pharmaceuticals
|
-- | -$5.8M | -- | -- | -- | -$2M |
|
IFRX
InflaRx NV
|
-$3M | -$10.4M | -56.78% | -56.78% | 1207051.66% | -$12.3M |
|
LENZ
LENZ Therapeutics
|
-- | -$15.2M | -- | -- | -- | -$9.2M |
|
MAZE
Maze Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -$29.4M | -- | -- | -- | -- |
Qiagen NV vs. Competitors
-
Which has Higher Returns QGEN or CDT?
Conduit Pharmaceuticals has a net margin of 16.95% compared to Qiagen NV's net margin of --. Qiagen NV's return on equity of 2.33% beat Conduit Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV63.95% $0.40 $5B CDTConduit Pharmaceuticals-- -$0.07 -- -
What do Analysts Say About QGEN or CDT?
Qiagen NV has a consensus price target of $49.48, signalling upside risk potential of 17.88%. On the other hand Conduit Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that Qiagen NV has higher upside potential than Conduit Pharmaceuticals, analysts believe Qiagen NV is more attractive than Conduit Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV5 8 0 CDTConduit Pharmaceuticals0 0 0 -
Is QGEN or CDT More Risky?
Qiagen NV has a beta of 0.624, which suggesting that the stock is 37.612% less volatile than S&P 500. In comparison Conduit Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or CDT?
Qiagen NV has a quarterly dividend of $1.30 per share corresponding to a yield of 0%. Conduit Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. Conduit Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or CDT?
Qiagen NV quarterly revenues are $521.2M, which are larger than Conduit Pharmaceuticals quarterly revenues of --. Qiagen NV's net income of $88.3M is higher than Conduit Pharmaceuticals's net income of -$6.5M. Notably, Qiagen NV's price-to-earnings ratio is 112.24x while Conduit Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 4.66x versus -- for Conduit Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV4.66x 112.24x $521.2M $88.3M CDTConduit Pharmaceuticals-- -- -- -$6.5M
-
Which has Higher Returns QGEN or IFRX?
InflaRx NV has a net margin of 16.95% compared to Qiagen NV's net margin of -14092.9%. Qiagen NV's return on equity of 2.33% beat InflaRx NV's return on equity of -56.78%.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV63.95% $0.40 $5B IFRXInflaRx NV-5376.61% -$0.09 $63.9M -
What do Analysts Say About QGEN or IFRX?
Qiagen NV has a consensus price target of $49.48, signalling upside risk potential of 17.88%. On the other hand InflaRx NV has an analysts' consensus of $9.24 which suggests that it could grow by 899.73%. Given that InflaRx NV has higher upside potential than Qiagen NV, analysts believe InflaRx NV is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV5 8 0 IFRXInflaRx NV4 1 0 -
Is QGEN or IFRX More Risky?
Qiagen NV has a beta of 0.624, which suggesting that the stock is 37.612% less volatile than S&P 500. In comparison InflaRx NV has a beta of 2.206, suggesting its more volatile than the S&P 500 by 120.591%.
-
Which is a Better Dividend Stock QGEN or IFRX?
Qiagen NV has a quarterly dividend of $1.30 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or IFRX?
Qiagen NV quarterly revenues are $521.2M, which are larger than InflaRx NV quarterly revenues of -$450. Qiagen NV's net income of $88.3M is higher than InflaRx NV's net income of -$5.4M. Notably, Qiagen NV's price-to-earnings ratio is 112.24x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 4.66x versus 299.60x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV4.66x 112.24x $521.2M $88.3M IFRXInflaRx NV299.60x -- -$450 -$5.4M
-
Which has Higher Returns QGEN or LENZ?
LENZ Therapeutics has a net margin of 16.95% compared to Qiagen NV's net margin of --. Qiagen NV's return on equity of 2.33% beat LENZ Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV63.95% $0.40 $5B LENZLENZ Therapeutics-- -$0.46 -- -
What do Analysts Say About QGEN or LENZ?
Qiagen NV has a consensus price target of $49.48, signalling upside risk potential of 17.88%. On the other hand LENZ Therapeutics has an analysts' consensus of $42.63 which suggests that it could grow by 110.39%. Given that LENZ Therapeutics has higher upside potential than Qiagen NV, analysts believe LENZ Therapeutics is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV5 8 0 LENZLENZ Therapeutics5 0 0 -
Is QGEN or LENZ More Risky?
Qiagen NV has a beta of 0.624, which suggesting that the stock is 37.612% less volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or LENZ?
Qiagen NV has a quarterly dividend of $1.30 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Qiagen NV pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or LENZ?
Qiagen NV quarterly revenues are $521.2M, which are larger than LENZ Therapeutics quarterly revenues of --. Qiagen NV's net income of $88.3M is higher than LENZ Therapeutics's net income of -$12.7M. Notably, Qiagen NV's price-to-earnings ratio is 112.24x while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 4.66x versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV4.66x 112.24x $521.2M $88.3M LENZLENZ Therapeutics-- -- -- -$12.7M
-
Which has Higher Returns QGEN or MAZE?
Maze Therapeutics has a net margin of 16.95% compared to Qiagen NV's net margin of --. Qiagen NV's return on equity of 2.33% beat Maze Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV63.95% $0.40 $5B MAZEMaze Therapeutics-- -- -- -
What do Analysts Say About QGEN or MAZE?
Qiagen NV has a consensus price target of $49.48, signalling upside risk potential of 17.88%. On the other hand Maze Therapeutics has an analysts' consensus of $25.67 which suggests that it could grow by 227.8%. Given that Maze Therapeutics has higher upside potential than Qiagen NV, analysts believe Maze Therapeutics is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV5 8 0 MAZEMaze Therapeutics3 0 0 -
Is QGEN or MAZE More Risky?
Qiagen NV has a beta of 0.624, which suggesting that the stock is 37.612% less volatile than S&P 500. In comparison Maze Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or MAZE?
Qiagen NV has a quarterly dividend of $1.30 per share corresponding to a yield of 0%. Maze Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. Maze Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or MAZE?
Qiagen NV quarterly revenues are $521.2M, which are larger than Maze Therapeutics quarterly revenues of --. Qiagen NV's net income of $88.3M is higher than Maze Therapeutics's net income of --. Notably, Qiagen NV's price-to-earnings ratio is 112.24x while Maze Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 4.66x versus -- for Maze Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV4.66x 112.24x $521.2M $88.3M MAZEMaze Therapeutics-- -- -- --
-
Which has Higher Returns QGEN or ORKA?
Oruka Therapeutics has a net margin of 16.95% compared to Qiagen NV's net margin of --. Qiagen NV's return on equity of 2.33% beat Oruka Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV63.95% $0.40 $5B ORKAOruka Therapeutics-- -$1.46 -- -
What do Analysts Say About QGEN or ORKA?
Qiagen NV has a consensus price target of $49.48, signalling upside risk potential of 17.88%. On the other hand Oruka Therapeutics has an analysts' consensus of $39.86 which suggests that it could grow by 409.67%. Given that Oruka Therapeutics has higher upside potential than Qiagen NV, analysts believe Oruka Therapeutics is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV5 8 0 ORKAOruka Therapeutics7 0 0 -
Is QGEN or ORKA More Risky?
Qiagen NV has a beta of 0.624, which suggesting that the stock is 37.612% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.582%.
-
Which is a Better Dividend Stock QGEN or ORKA?
Qiagen NV has a quarterly dividend of $1.30 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. Qiagen NV pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or ORKA?
Qiagen NV quarterly revenues are $521.2M, which are larger than Oruka Therapeutics quarterly revenues of --. Qiagen NV's net income of $88.3M is higher than Oruka Therapeutics's net income of -$28.6M. Notably, Qiagen NV's price-to-earnings ratio is 112.24x while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 4.66x versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV4.66x 112.24x $521.2M $88.3M ORKAOruka Therapeutics-- -- -- -$28.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will JP Morgan’s AI Advisor Be a Winner?
JPMorgan Chase is rolling out “JPM WealthAI for high-net-worth clients.…
Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
